Genmab A/S (STU:GE91) Ending Cash Position : €1,967 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S Ending Cash Position?

Genmab A/S's Ending Cash Position for the quarter that ended in Mar. 2024 was €1,967 Mil.

Genmab A/S's quarterly Ending Cash Position increased from Sep. 2023 (€1,914 Mil) to Dec. 2023 (€1,995 Mil) but then declined from Dec. 2023 (€1,995 Mil) to Mar. 2024 (€1,967 Mil).

Genmab A/S's annual Ending Cash Position increased from Dec. 2021 (€1,205 Mil) to Dec. 2022 (€1,330 Mil) and increased from Dec. 2022 (€1,330 Mil) to Dec. 2023 (€1,995 Mil).

Genmab A/S Ending Cash Position Historical Data

The historical data trend for Genmab A/S's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Ending Cash Position Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

475.51

975.85

1,204.52

1,329.79

1,994.65

Genmab A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															1,650.84	1,460.54	1,913.91	1,994.65	1,967.46

Genmab A/S Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Genmab A/S's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1327.308	+	667.343
	=	1,995

Genmab A/S's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1993.883	+	-26.42
	=	1,967

Genmab A/S Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (STU:GE91) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (STU:GE91) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (STU:GE91) Headlines

No Headlines